Company Overview of Appistry Inc.
Appistry Inc. provides analytics and data management solutions to corporations, Fortune 100 companies, and government agencies worldwide. It offers Ayrris, an open, scalable solution for data-intensive applications. The company also provides AYRRIS/BIO–NGS Analytics that employs analytical pipelines designed to automate the analysis and management of specific types of data; and AYRRIS/BIO–Data Management, which provides data management solutions adapted to support NGS Analytics for the life sciences sector. In addition, it offers Ayrris/DEFENSE that offers high-volume data ingest, storage, analysis, and delivery for the intelligence and defense organizations; Appistry CloudDx, a cloud-based ...
10845 Olive Boulevard
St. Louis, MO 63141
Founded in 2001
Key Executives for Appistry Inc.
Compensation as of Fiscal Year 2014.
Appistry Inc. Key Developments
Appistry Teams with Personal Genome Diagnostics to Offer CancerSelect Test through Appistry CloudDx
May 30 14
Appistry, Inc. announced an agreement with Personal Genome Diagnostics to include the company's CancerSelect(TM) panel in Appistry's recently released Appistry CloudDx(TM) genomics testing service. PGDx is among the first organizations to offer lab-developed tests (LDTs) through Appistry's cloud-based service that makes LDTs from leading diagnostic test providers available to physicians across the United States. CancerSelect targets 120 genes of clinical and biological importance to cancer, providing information that can help physicians individualize treatment to a patient's cancer. The CancerSelect panel is sequenced in PGDx's CLIA-certified laboratory, and the analysis is conducted using PGDx's proprietary algorithms that provide extremely high coverage, copy number analyses for 63 genes, and translocation analysis for 17 genes. Appistry will collaborate with PGDx to deliver a report to participating physicians containing a pathological evaluation of the tumor sample; tumor-specific mutations (alterations and substitutions, amplifications, and translocations); a description of mutated genes and pathways along with biologic and clinical implications; full statistics; and therapeutic, predictive, and prognostic information and references, as well as referral information for ongoing clinical trials that might be relevant based on the analysis results. Appistry CloudDx streamlines and simplifies the workflow associated with genomics-based testing, which has been limited in its impact, partly because it requires organizations to amass infrastructure and expertise to deliver relevant results that are usable by physicians. Appistry CloudDx provides a single web dashboard for ordering and tracking the progress of tests and orchestrates the data flow between test providers such as PGDx and requesting physicians and hospitals, thereby ensuring that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines.
Appistry, Inc. Launches Appistry CloudDx(TM)
May 30 14
Appistry Inc. announced the launch of Appistry CloudDx(TM), a cloud-based service for ordering genomics tests. By collecting established laboratory-developed tests (LDTs) in a single, easy-to-access environment and streamlining the processes associated with delivering clinically relevant results to physicians, Appistry CloudDx aims to place the genomically enhanced medicine now practiced at academic medical centers within the reach of community physicians and regional hospitals. Appistry CloudDx provides a web-based dashboard for ordering established LDTs and tracking the status of individual orders across healthcare organizations. The cloud based system orchestrates the flow of data and logistics among the network of service providers often needed to sequence samples, analyze sequencing data, and interpret the results for physicians. This orchestration ensures that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines and that all processes essential for the rapid delivery of results to physicians occur consistently and efficiently. Appistry CloudDx will include established LDTs from diagnostic test providers covering a range of diseases. Currently, the system includes panels and tests for cardiomyopathy, hearing loss, lung disease, and whole genome sequencing developed by Partners HealthCare Personalized Medicine. Additional tests and test partners will be announced in the coming weeks. It is estimated that approximately 80—90% of oncology occurs in a community setting. Yet these physicians are the least likely to have access to the infrastructure to support genomics testing or the expertise to apply it to patient care. For genomics to become a routine part of disease diagnosis and treatment, all physicians - regardless of geography, institutional size, or medical system affiliation - need easy ways to access tests and receive relevant results. Additionally, the simplified workflow provided by Appistry CloudDx will enable hospitals to begin measuring and quantifying how genomics tests improve patient care and outcomes. Evidence of improved patient care and cost reductions due to genomics testing will be key in convincing insurance companies to cover the services.
Bina Technologies Announces Distribution Agreement with Appistry
Apr 21 14
Bina Technologies announced a distribution agreement with Appistry Inc., which enables Bina to include runtime licenses for the Genome Analysis Toolkit (GATK) and Cancer Genome Analysis (CGA) Suite NGS analysis tools as integral parts of the Bina Analytics genomics platform. Effective immediately, all of Bina's on-premises genomic analysis solutions, including both Bina Enterprise and Bina Desktop products, will integrate the GATK and CGA Suite, including MuTect for cancer genome analysis, into the Bina Analytics pipeline. The CGA Suite, only available from Appistry, includes several Broad-built tools for somatic mutation analysis, including MuTect, ContEst (for estimating contamination in datasets), and Somatic Indel Detector.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 30, 2013